NASDAQ:CASI - CASI Pharmaceuticals Stock Price, Forecast & News

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

CASI Pharmaceuticals Inc (NASDAQ:CASI) announced its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.01. The biotechnology company earned $2.79 million during the quarter, compared to analysts' expectations of $0.70 million. View CASI Pharmaceuticals' Earnings History.

CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for CASI Pharmaceuticals.

1 Wall Street analysts have issued 1 year price objectives for CASI Pharmaceuticals' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate CASI Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 131.0% from the stock's current price. View Analyst Price Targets for CASI Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CASI Pharmaceuticals.

News coverage about CASI stock has been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CASI Pharmaceuticals earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for CASI Pharmaceuticals.

Some companies that are related to CASI Pharmaceuticals include NanoString Technologies (NSTG), Mesoblast (MESO), DBV TECHNOLOGIE/S (DBVT), Aerie Pharmaceuticals (AERI), Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO), AVITA MED LTD/S (RCEL), Oyster Point Pharma (OYST), Vericel (VCEL), Proteon Therapeutics (PRTO), Adverum Biotechnologies (ADVM), Atara Biotherapeutics (ATRA), GENFIT S A/ADR (GNFT) and Twist Bioscience (TWST).

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include Caladrius Biosciences (CLBS), Frontier Communications (FTR), Celsion (CLSN), Catalyst Pharmaceuticals (CPRX), InterDigital Wireless (IDCC), Bank of Hawaii (BOH), Energy Transfer LP Unit (ET), Novavax (NVAX), Progenics Pharmaceuticals (PGNX) and Rigel Pharmaceuticals (RIGL).

Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CASI stock can currently be purchased for approximately $3.03.

CASI Pharmaceuticals has a market capitalization of $291.94 million. The biotechnology company earns $-27,470,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe.View Additional Information About CASI Pharmaceuticals.

The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com/.

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]